Crystalline forms of dexamethasone dimers and uses thereof
AssigneeRipple Therapeutics Corporation
InventorsIan Charles Parrag, Matthew Alexander John Statham, Emma-Louise Elizabeth Moore, Bahareh Khalili, Judith Anne Williams, Elizabeth Poloz, Boris Gorin
Life of this patent
Estimating the term…
Abstract
The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21′-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.
Claims12
A solid crystalline form of a compound represented by the following formula:
- the solid crystalline form being characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at:
- 3.8°±0.2° 2θ, 7.6°±0.2° 2θ, 8.8°±0.2° 2θ, 9.72±0.2° 2θ, and 12.2°±0.2° 2θ.
A solid crystalline form of a compound represented by the following formula:
- the solid crystalline form being characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at:
- 3.9°±0.2° 2θ, 7.9°±0.2° 2θ, 9.7°±0.2° 2θ, 12.0°±0.2° 2θ, and 15.9°±0.2° 2θ.
A solid crystalline form of a compound represented by the following formula:
- the solid crystalline form being characterized by an X-ray powder diffraction XRPD pattern comprising peaks at:
- 8.9°±0.2° 2θ, 11.4°±0.2° 2θ, 14.1°±0.2° 2θ, 16.4°±0.2° 2θ, and 17.1°±0.2° 2θ.
Dependencies are inferred from the claim text.